Accendra Health account plan
home-based care medical products
At a glance
Accendra Health (formerly Owens & Minor) is a US home-based care company, behind the Apria and Byram brands, with FY2025 net revenue of $2,762 million.
Accendra Health, Inc. (NYSE: ACH), the former Owens & Minor, became a pure home-based care company after selling its Products & Healthcare Services business on December 31, 2025. Through its Apria and Byram Healthcare brands it rents and sells home medical equipment and supplies across the United States: diabetes supplies, sleep therapy, home respiratory therapy, ostomy, wound care and urology. FY2025 net revenue from continuing operations was $2,762 million, up 3.1%, with adjusted EBITDA (non-GAAP) of $374.8 million and a GAAP loss from continuing operations of $102.7 million. Headquartered in Richmond, Virginia, it had over 6,500 teammates and more than 250 locations at the end of 2025.
Business units
Diabetes
about 28% of FY2025 net revenue ($783.4 million)Diabetes supplies and devices delivered to patients' homes, the largest category. Q3 2026 revenue was $195.6 million, down 2.9%, as insulin pump growth could not offset declines in CGMs.
Sleep therapy
about 27% of FY2025 net revenue ($740.1 million)CPAP and bi-level devices, patient support and resupply for obstructive sleep apnea, helped by the Sleep Journey Initiative and a Sleep Center of Excellence. Q3 2026 revenue was $144.5 million, down 22.2% with the lost payer, though sleep grew over 4% on a like-for-like basis.
Home respiratory therapy
about 16% of FY2025 net revenue ($433.1 million)Home oxygen and non-invasive ventilation. Q3 2026 revenue was $88.9 million, down 17.1%; the CEO says the company has lost share in this market.
Ostomy
about 8% of FY2025 net revenue ($212.8 million)Ostomy supplies; revenue grew 8.6% in 2025, and nine-month 2026 revenue grew 4.9% to $162.2 million.
Wound care
about 7% of FY2025 net revenue ($188.5 million)Wound care products including negative pressure wound therapy; Q3 2026 revenue was $41.6 million, down 13.3%.
Urology
about 4% of FY2025 net revenue ($116.0 million)Urology supplies; revenue grew 8.3% in 2025, and nine-month 2026 revenue grew 4.6% to $89.8 million.
Other home medical equipment
about 10% of FY2025 net revenue ($288.2 million)Other home medical equipment, incontinence and other products and services; Q3 2026 revenue was $47.2 million, down 35.0% after a non-core asset sale.
Strategic priorities
- Win referrals
- Improve go-to-market and intake in respiratory and sleep, including faster adoption of e-prescribe digital referral management, which sits below industry peers; commercial operations now report to Chief Commercial Officer Scott Lloyd.
- Keep patients on therapy
- Supporting patients after setup becomes a North Star KPI, as material portions of new sleep patients lapse before the 90-day compliance window.
- Revenue cycle management
- Clean orders, on-time filing, fewer denials and faster rework, after weak collections hit revenue and adjusted EBITDA by nearly $20 million in the first half of 2026.
- Rebuild branches and back office
- Simplify and automate processes to cut cost to serve, with a first revamped version launching in Q1 and a transformation office running quarterly hard-dollar targets.
- Deleveraging
- Management targets long-range leverage of 3x adjusted EBITDA; net debt was $1.73 billion after Q3 2026, with no refinancing due until early 2029.
Latest results
In Q3 2026 net revenue fell 13.7% to $601.8 million (Q3 2025: $697.3 million), mainly because terminated commercial Payor contracts cost $82 million in the quarter; excluding that and a non-core asset sale, revenue was down 1%. Adjusted EBITDA (non-GAAP) was $47.8 million against $92.2 million, and the GAAP loss from continuing operations was $18.0 million. Cost of net revenue rose to 56.6% of revenue on lower collection rates. Full-year net revenue is now expected at the bottom end of the $2.45 billion to $2.55 billion range, and adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of the prior outlook range.
Investments and deals
- Sale of Products & Healthcare Services
- Sold on December 31, 2025 for $375 million in cash, subject to adjustments, keeping a 5% equity interest; the business had $7,910 million of 2025 net revenue.
- Balance Sheet Optimization Transaction
- In June 2026 the 2029 and 2030 notes were exchanged for 9.000% first-lien notes due 2032 ($539 million) and 9.750% second-lien notes due 2033 ($698 million); Term Loan A was repaid.
- Patient service equipment
- Continuing-operations capex was $201 million in 2025, mostly patient service equipment; the CFO expects capex to be quite a bit lower in 2027 than 2026.
- Terminated Rotech acquisition
- The planned Rotech deal was terminated in June 2025, with an $80 million breakage fee paid to Rotech.
Challenges and risks
- Payor concentration
- The two largest commercial Payors were about 23% and 14% of 2025 net revenue; one terminated contracts worth $322 million, or 12% of 2025 net revenue.
- Share loss and patient attrition
- The CEO says the company has lost share in sleep and respiratory while the markets grew, citing high friction, slow order intake and inconsistent sales execution.
- Liquidity and listing
- Cash fell to $26.6 million at September 30, 2026, the total deficit was $568.2 million, and the NYSE sent notices on the share price below $1.00 and on market capitalisation and equity below $50 million.
- Regulation and reimbursement
- The June 2025 CMS coverage determination tightens home NIPPV qualification for COPD patients, alongside DMEPOS competitive bidding and Apria's Corporate Integrity Agreement.
- Supplier dependence
- The three largest suppliers made up about 40% of purchases in 2025.
What leadership says
“In sleep and respiratory, 2 of our most attractive businesses, we have lost share while the markets grew.”
“Our goal is to shift branches towards patient service and clinical hubs, not administrative warehouses.”
“The quarter was extremely disappointing as most of the near-term profit improvement efforts over the last few months did not yield the expected results.”
“We're entering 2026 as a much leaner and more nimble business with a much higher margin profile”
Where a supplier can help
- Digital referral and intake
- Tied to the win-referrals priority: e-prescribe and order-intake software can raise digital referral adoption that sits below industry peers and reduce order rework.
- Revenue cycle and denials management
- Tied to the revenue cycle priority: claims, documentation and denials tools address collection rates that cost nearly $20 million in the first half of 2026.
- Patient adherence engagement
- Tied to the keep-patients-on-therapy priority: outreach and remote-monitoring tools can help new sleep patients reach the 90-day compliance window and return for resupply.
- Back-office automation and logistics
- Tied to the branch and back-office rebuild: automation and fulfilment partners fit a plan to cut cost to serve; the company already moved some fulfilment to logistics providers.
- Cash-conscious commercial terms
- Tied to the liquidity challenge: suppliers offering pay-for-performance or savings-backed pricing match a company with $26.6 million of cash and hard-dollar targets.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Accendra Health?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Accendra Health (f/k/a Owens & Minor) Annual Report on Form 10-K for fiscal year 2025
- Accendra Health, Inc. is the former Owens & Minor, Inc., renamed after it sold its Products & Healthcare Services (P&HS) business on December 31, 2025 for $375 million in cash (subject to adjustments), keeping a 5% equity interest. What remains is a single-segment, US-only home-based care company built on the Apria and Byram Healthcare brands (plus the Lofta trademark), headquartered in Richmond, Virginia.
- FY2025 net revenue from continuing operations was $2,762 million, up 3.1% from $2,680 million. Diabetes ($783 million), sleep therapy ($740 million) and home respiratory therapy ($433 million) are the three largest categories, followed by ostomy, wound care and urology. Sleep therapy (+5.3%), ostomy (+8.6%) and urology (+8.3%) drove the growth, helped by the Sleep Journey Initiative.
- Adjusted EBITDA (non-GAAP) was $374.8 million (2024: $370.5 million) and free cash flow (non-GAAP) was $98.3 million. The GAAP loss from continuing operations was $102.7 million, or $(1.34) per share. That loss includes an $80 million breakage fee paid to Rotech when the planned acquisition was terminated in June 2025. Discontinued P&HS lost $998 million after tax, including a $799 million loss on classification as held for sale.
- Payor concentration is the biggest risk. The two largest commercial Payors were about 23% and 14% of net revenue, and Medicare/Medicaid about 19%. One commercial Payor is terminating contracts worth $322 million, or 12% of 2025 net revenue, including $231 million of capitation revenue (nearly all of the company's capitation revenue). The transition runs through the first half of 2026.
- Debt is heavy: $2.1 billion of principal at December 31, 2025. Term Loan A ($326 million) and the revolver ($204 million drawn) mature in March 2027, Term Loan B ($511 million) in March 2029, and notes of $479 million and $552 million in 2029 and 2030. Cash was $282 million.
- The company has over 6,500 teammates, none unionised, and more than 250 locations, including a national pharmacy and a biomedical repair center.
- Leadership: Edward A. Pesicka (President & CEO since 2019), Jonathan A. Leon (EVP & CFO), Perry Bernocchi (EVP & COO, ex-CEO of Byram Healthcare and Patient Direct) and Heath Galloway (EVP, General Counsel, also over HR since January 2026).
- Further regulatory and operating risks: the June 2025 CMS national coverage determination tightens home NIPPV qualification for COPD patients; Apria's Corporate Integrity Agreement is expected to close in 2026; three suppliers make up about 40% of purchases; DMEPOS competitive bidding.
- Accendra Health Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 net revenue fell 13.7% to $601.8 million (Q3 2025: $697.3 million). Over nine months it fell 10.2% to $1,842.8 million. Most of the decline is the terminated commercial Payor contracts, which cost $82 million of revenue in the quarter and $205 million over nine months.
- Excluding the Payor termination and a sold non-core asset, home respiratory therapy, diabetes and wound care fell in Q3, while sleep therapy grew by $5.6 million and ostomy by $2.0 million.
- Q3 adjusted EBITDA (non-GAAP) was $47.8 million, against $92.2 million a year earlier. The GAAP loss from continuing operations was $18.0 million, or $(0.23) per share. Cost of net revenue rose to 56.6% of revenue (from 53.8%) because collection rates were lower, and SG&A rose to 41.5% of revenue.
- In June 2026 a "Balance Sheet Optimization Transaction" exchanged almost all of the 2029 and 2030 unsecured notes for 9.000% first-lien notes due 2032 ($539 million) and 9.750% second-lien notes due 2033 ($698 million). Term Loan A was repaid. The $300 million revolver now matures in January 2030. Cash was $26.6 million at September 30, 2026.
- Leadership change: on October 5, 2026 Kenneth Gardner-Smith succeeded Edward A. Pesicka as President and CEO. Scott Lloyd joined in a newly created Chief Commercial Officer role covering commercial strategy, sales and provider and payor partnerships.
- The 10-Q acknowledges "recurring losses and cash outflows from operating activities during 2026" and says the company depends on a value creation plan: cost savings, growth in sleep and respiratory, and revenue cycle optimisation.
- In October 2026 the NYSE sent two notices: the share price was below $1.00, and both market capitalisation and stockholders' equity were below $50 million. The company plans a reverse stock split in the range of 1-for-20 to 1-for-30.
- Accendra Health Reports Third Quarter 2026 Financial Results (press release, Exhibit 99.1)
- Q3 2026 net revenue was $601.8 million (Q3 2025: $697.3 million). Year to date it was $1,842.8 million (2025: $2,053.1 million).
- Q3 adjusted EBITDA (non-GAAP) was $47.8 million, against $92.2 million. Year-to-date adjusted EBITDA was $166.2 million, against $284.8 million.
- Q3 free cash flow (non-GAAP) was $5.8 million. Year to date it was negative $21.3 million, against positive $80.0 million in 2025.
- Outlook was cut again: full-year net revenue is expected at the bottom end of the $2.45 billion to $2.55 billion range, and adjusted EBITDA "could be as much as 30% lower than the $310 million midpoint" of the prior outlook range.
- The new CEO, Kenny Gardner-Smith, says 2026 results "have fallen well short of our expectations and potential". He has identified four key areas and promises a value creation plan with details "in the coming months".
- The balance sheet shows cash of $26.6 million, long-term debt of $1,720.0 million and a total deficit of $568.2 million at September 30, 2026.
- Accendra Health Q3 2026 earnings call transcript
- This is the new CEO Kenny Gardner-Smith's first call (he took over in October 2026 after years on the board). He says most of the company's issues "are fixable and largely within our control", and that "we will not be in a period of prolonged diagnosis".
- His diagnosis: in sleep and respiratory, "we have lost share while the markets grew". He points to high friction for customers, slow and costly order intake, low e-prescribe adoption, patients lapsing before the 90-day compliance window, and inconsistent sales execution.
- The plan has four pillars: (1) winning referrals, (2) supporting patients over the life of their therapy, (3) optimising revenue cycle management, and (4) rebuilding the back office and branch operating system to cut "cost to serve".
- Organisation changes:
- Commercial operations and commercial contracting are consolidated under the new Chief Commercial Officer, Scott Lloyd.
- COO Perry Bernocchi has moved to an advisory role, and the CEO now oversees branches and the back office directly.
- A dedicated transformation function will run the multi-year plan with quarterly hard-dollar targets.
- Revamped branch and back-office operations launch in Q1.
- CFO Jon Leon: Q3 revenue was "just under $602 million", down 1% excluding the lost large commercial payer and the non-core asset sale. Sleep grew over 4%, diabetes fell nearly 3%, and respiratory and wound fell about 6.5% and 6%. Adjusted EBITDA was $47.8 million.
- Liquidity: net debt is $1.73 billion, there is "nearly $300 million of available liquidity", and the first refinancing is not due until early 2029. Full-year adjusted EBITDA could be as much as 30% below the $310 million midpoint, with Q4 similar to Q3. Expectations for 2027 come early next year.
- Accendra Health Q2 2026 earnings call transcript
- Ed Pesicka announces his intention to retire as CEO by the end of 2026 after nearly eight years. He credits himself with stabilising the company, steering it through COVID, selling P&HS and optimising the balance sheet, which "transformed the company into a focused, pure-play, home-based healthcare business".
- Q2 missed expectations for three reasons: revenue growth was below plan, planned cost reductions came late, and collection rates recovered slowly. Weak collections hit revenue and EBITDA by "nearly $20 million in the first half".
- Commercial wins:
- The largest soft-goods contract with the largest commercial payer was renewed.
- A new sole-source agreement with a regional health system was signed, to launch in early 2027.
- An enterprise-wide fee-for-service agreement was signed with another payer.
- Costs: "more than $125 million of annualized costs" were eliminated after the separation and the payer exit, and a next phase of cuts started in Q3. New logistics-provider arrangements for fulfilment are planned, and the national rollout of the Sleep Center of Excellence continues.
- CFO Jon Leon: like-for-like revenue grew 2% (sleep about 5.5%, diabetes 4%, ostomy and urology high single digits; respiratory and wound down). Adjusted EBITDA was "just over $60 million". Total debt of $1.72 billion was down almost $400 million since March, with no maturities until 2029.
- Guidance was cut to $2.45 billion to $2.55 billion of revenue and $300 million to $320 million of adjusted EBITDA. Free cash flow is now expected "break even to slightly positive". The company plans an at-the-market equity program and an NOL rights plan to protect more than $200 million of NOLs.
- Accendra Health Q4 2025 earnings call transcript
- This was the "very first earnings call as Accendra Health" after the December 31, 2025 sale of the Products & Healthcare Services business "to Platinum Equity". Pesicka pitches a pure-play home-based care leader. Its payer relationships reach "approximately 300 million Americans", and Byram and Apria are its two go-to-market brands.
- Growth themes:
- the sleep journey initiative (sleep supplies grew 8%-9% for the quarter and the year)
- a new myApria app expected in Q2 2026
- technology to automate payer qualification
- Medicare competitive bidding in diabetes, urology and ostomy, which Pesicka sees as an opportunity
- CFO Jon Leon: 2025 revenue was "nearly $2.8 billion, up a little more than 3%" and adjusted EBITDA $375 million. Continuing operations generated $154 million of operating cash flow and $98 million of free cash flow. Net debt was $1.8 billion at December 31.
- The lost large commercial payer means a revenue impact of about $300 million in 2026 and another $40 million in 2027. A preferred-provider agreement with Optum is meant to help backfill it.
- 2026 guidance: revenue of $2.55 billion to $2.65 billion, adjusted EBITDA of $335 million to $355 million and at least $100 million of free cash flow at the midpoint. About 60% of EBITDA is expected in the second half.
- Priorities: deleveraging (long-range leverage target of 3x adjusted EBITDA), "metered investments" in technology, possibly small tuck-in M&A, and optimising the capital structure "in the near term".
Questions about Accendra Health
What does Accendra Health do?
Accendra Health rents and sells home medical equipment and supplies in the US through its Apria and Byram Healthcare brands, covering diabetes, sleep therapy, home respiratory therapy, ostomy, wound care and urology.
What is Accendra Health's revenue?
FY2025 net revenue from continuing operations was $2,762 million. Q3 2026 net revenue was $601.8 million, and full-year 2026 revenue is expected at the bottom end of $2.45 billion to $2.55 billion.
How many employees does Accendra Health have?
Over 6,500 teammates at the end of 2025, across more than 250 locations.
Who leads Accendra Health?
Kenneth Gardner-Smith succeeded Edward A. Pesicka as President and CEO on October 5, 2026. Jonathan A. Leon is EVP and CFO and Scott Lloyd is Chief Commercial Officer.
Is Accendra Health the same as Owens & Minor?
Accendra Health is the former Owens & Minor, Inc., renamed after it sold its Products & Healthcare Services business on December 31, 2025.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)